Look forward to an exciting WebUp on tezepelumab, a monoclonal antibody with a new mode of action targeting TSLP, which is indicated for the treatment of severe uncontrolled asthma. Prof. Andrew Menzies-Gow, MD (Royal Brompton & Harefield Hospitals, London, UK), international expert in severe asthma and principal investigator of the phase III NAVIGATOR trial, will guide you through this WebUp.
This WebUp will be held in English. Participation in the WebUp is free of charge.
Referent/innen
Prof. Andrew Menzies-Gow
Pneumologie
Content
The goal of this WebUp is to inform you about the most important study data on tezepelumab and to show you the significance of this new therapeutic option in severe asthma. Prof. Menzies-Gow will share his experiences with tezepelumab and discuss patient cases with you. We then venture into the topic of remission in severe asthma. Afterwards, we look forward to your interesting questions and having a lively discussion with you.
Target group
Specialists in allergology, pneumology, immunology and other interested specialists.
In friendly cooperation with
General informations
-
This broadcast is made available to you free of charge. To view the broadcast, click on «Login» before the broadcast starts and log in with your FomF account. If you do not have an account yet, you can create one by clicking on «Register».
-
By clicking on «Termin vormerken» you will receive an e-mail 3 hours before the start of the broadcast and / or, if you wish, an SMS reminder 15 minutes before the start of the broadcast.
-
To ask questions during the broadcast, please click on the speech bubble at the bottom right of the screen & you will be able to ask your questions in the chat room.
-
Missed the broadcast? No problem, after 24 hours the recording of the broadcast will be available for you on this page OnDemand.
-
If you have technical questions about the stream, please visit our FAQ page.